Why Mindtree founder Subroto Bagchi, who donated Rs 1000000000, still holds Re 1 Cheque?
This Rs 1 cheque wasn't payment for consulting a company or startup. It was his final salary for serving as the Chief Advisor to the Government of Odisha. Bagchi held this post for eight years and accepted only Rs 1 as his annual salary as a symbolic gesture that shows his commitment to public service over financial reward.
Bagchi wrote: '' What is the biggest wealth in this one life that I would never ever part with? Well, for every year of the work I did with the government, the deal was, they pay me Rs 1. For the 8 years out there, I got 8 cheques & this one here was my last salary drawn.''
What is the biggest wealth in this one life that I would never ever part with? Well, for every year of the work I did with the government, the deal was, they pay me Rs 1. For the 8 years out there, I got 8 cheques & this one here was my last salary drawn 🙏 pic.twitter.com/nVx2EZWv7K
— Subroto Bagchi (@skilledinodisha) July 5, 2025 Who Is Subroto Bagchi?
Subroto Bagchi is known as the co-founder of Mindtree, an IT and consulting firm. He has received many awards for his leadership, vision, and philanthropy. He has substantial wealth but this Rs 1 cheque holds the deepest meaning for him. He and his wife, Susmita Bagchi, have donated hundreds of crores for causes like cancer care and skill development.
While many business leaders ask for high payments for advisory roles, Bagchi made it clear that his motivation was never money. It was a sense of duty towards his home state, Odisha. His service was quiet and selfless.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
18 minutes ago
- Time of India
Income Tax refunds jump 474% since 2013-14, issuance time improves in past 11 years
Synopsis India's Income Tax refunds have surged by 474% over the past 11 years, reaching Rs 4.77 lakh crore in 2024-25, outpacing the 274% growth in gross tax collections. The processing time for refunds has significantly decreased from 93 days in 2013 to just 17 days in 2024. This improvement is attributed to enhanced tax administration and digital infrastructure.
Time of India
20 minutes ago
- Time of India
Tech Park: Karnataka CM Siddaramaiah's meeting on Tuesday to decide on farmers offer to sell their land for Rs 3.5 cr per acre
Protesting farmers from Devanahalli have offered to give up 449 acres near the international airport for the proposed high-tech park if the government fixes a rate of Rs 3.5 crore per acre . The state government will take a decision on the demand at July 15 meeting to be chaired by Chief Minister Siddaramaiah. Industries Minister MB Patil , speaking to the media on Sunday, said he hoped a solution would emerge on Tuesday. The farmers are demanding higher compensation, suitable jobs for locals who are giving up their lands and declaring the surrounding areas as a yellow zone. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Rates Patil said the government was keen to balance the interests of farmers with the need for industrialization. There are also demands from local protestors to preserve the agricultural lands, which has led to a thinking in the government to declare the region as a green zone. The government, the minister added, was aware not all protesters were genuine farmers and some of them have already entered into agreements with big builders agreeing to sell their lands for real estate. Live Events Farmers of Channarayapatna hobli in Bengaluru rural district have been on a protest seeking to stall the acquisition. The previous BJP regime had, on August 27, 2021, issued a preliminary notification proposing acquisition of 1,772.2 acres of land from 13 villages in Channarayapatna hobli. Patil, the industries minister, had said last month that the process of acquiring the remaining 1,232 acres of land will go on as planned before.
Economic Times
21 minutes ago
- Economic Times
Cipla eyes entry into India's weight management market amid rising demand and global competition
Synopsis Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader. Agencies Representative image Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25."Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders."Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added."Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability."We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
